D-dimer is an important biomarker used to assess the risk of a person developing a deep vein thrombosis (DVT) or pulmonary embolism (PE). It is a short fragment of a protein called fibrin that is produced by the body during the clotting process. The presence of elevated levels of D-dimer in the blood can indicate an increased risk of developing a DVT or PE, and can be used to help diagnose and treat these conditions. However, the normal ranges of D-dimer can vary greatly depending on a person’s age. It is important for doctors to understand the normal ranges of D-dimer by age in order to accurately assess a patient’s risk of developing a DVT or PE. This guide will provide an overview of D-dimer normal ranges by age, and discuss how these ranges can be used to assess a patient’s risk of developing a DVT or PE.
D-dimer is a protein fragment produced by the body during the clotting process. It is a short fragment of a larger protein called fibrin, which is produced when the body's clotting factors are activated. D-dimer is released into the bloodstream when a clot is being formed, and its levels can be measured in a blood test. The presence of elevated levels of D-dimer in the blood can indicate an increased risk of developing a DVT or PE. This is because elevated levels of D-dimer can indicate that a clot is forming in the veins or arteries, which can lead to a DVT or PE.
The normal ranges of D-dimer vary greatly depending on a person’s age. In general, the normal range of D-dimer is lower in younger individuals and increases with age. For adults aged 18-50, the normal range of D-dimer is typically 0-0.5 mcg/mL. For adults aged 50-75, the normal range is typically 0.5-1.0 mcg/mL. For adults aged 75 and older, the normal range is typically 1.0-2.0 mcg/mL. In addition to age, other factors can affect the normal range of D-dimer, such as gender, body weight, and health conditions. For example, women tend to have higher levels of D-dimer than men, and people with certain health conditions, such as cancer, may have higher levels of D-dimer than those without the condition.
D-dimer normal ranges can be used to assess a person’s risk of developing a DVT or PE. If a person’s D-dimer levels are higher than the normal range for their age, it may indicate an increased risk of developing a DVT or PE. In addition, doctors can use D-dimer normal ranges to help diagnose a DVT or PE. If a person has a D-dimer level that is higher than the normal range for their age, it may indicate that they have a DVT or PE.
D-dimer is an important biomarker used to assess the risk of a person developing a deep vein thrombosis (DVT) or pulmonary embolism (PE). The normal ranges of D-dimer vary greatly depending on a person’s age, and it is important for doctors to understand these ranges in order to accurately assess a patient’s risk of developing a DVT or PE. D-dimer normal ranges can also be used to help diagnose a DVT or PE. By understanding D-dimer normal ranges by age, doctors can more accurately assess a patient’s risk of developing a DVT or PE.
1.
Cancer care crowdfunding increasingly common, but rarely successful
2.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
3.
Researchers discover that children who survive cancer have socioeconomic challenges.
4.
Could CT scans be fueling a future rise in cancer cases, as a new study suggests?
5.
SBRT May Beat Brachytherapy in Prostate Cancer
1.
Exploring the Normal Range of Monocytes: A Comprehensive Guide
2.
Breast Cancer Recovery: Fashion, Function, and Healing Beyond Scars
3.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
4.
Value, Access, and Affordability in Next-Gen Oncology: Navigating Costs, Coverage, and Clinical Impact
5.
The Importance of Early Detection: How Genetics Play a Role in Leucocythemia Diagnosis
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A New Era in Managing Cancer-Associated Thrombosis
2.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation